154 related articles for article (PubMed ID: 37215611)
1. The potential of low-dose-rate brachytherapy with iodine-125 in the treatment of local recurrences of prostate cancer after primary high-dose-rate monotherapy.
Burchardt WM; Chyrek AJ; Bielęda GM; Burchardt E; Chicheł A
J Contemp Brachytherapy; 2023 Apr; 15(2):103-109. PubMed ID: 37215611
[TBL] [Abstract][Full Text] [Related]
2. Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity.
Henríquez I; Sancho G; Hervás A; Guix B; Pera J; Gutierrez C; Abuchaibe O; Martínez-Monge R; Tormo A; Polo A
Radiat Oncol; 2014 Apr; 9():102. PubMed ID: 24885287
[TBL] [Abstract][Full Text] [Related]
3. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
4. Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer.
Armstrong S; Tsang Y; Lowe G; Tharmalingam H; Alonzi R; Ostler P; Hughes R; Hoskin P
Radiother Oncol; 2021 Apr; 157():93-98. PubMed ID: 33493500
[TBL] [Abstract][Full Text] [Related]
5. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
[TBL] [Abstract][Full Text] [Related]
6. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control.
Mayrata E; Espinosa JM; Büchser D; Casquero F; Suárez F; González A; Minguez P; Pérez JF; Miguel IS; Cacicedo J; Gómez-Iturriaga A
J Contemp Brachytherapy; 2021 Feb; 13(1):12-17. PubMed ID: 34025731
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of salvage high dose-rate brachytherapy with or without pelvic external beam radiotherapy in patients with palpable local recurrence of prostate cancer after radical prostatectomy.
Ni L; Chen K; Phuong C; Sabbagh AR; Wong AC; Mohamad O; Hsu IC
Brachytherapy; 2023; 22(3):304-309. PubMed ID: 36623988
[TBL] [Abstract][Full Text] [Related]
8. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
9. Low-/high-dose-rate brachytherapy boost in patients with intermediate-risk prostate cancer treated with radiotherapy: long-term results from a single institution team experience.
Villalba SR; Denia PM; Pérez-Calatayud MJ; Sancho JR; Pérez-Calatayud J; Escrivá AF; Tendero PT; Ortega MS
J Contemp Brachytherapy; 2021 Apr; 13(2):135-144. PubMed ID: 33897786
[TBL] [Abstract][Full Text] [Related]
10. Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer.
Burchardt W; Skowronek J
J Contemp Brachytherapy; 2018 Feb; 10(1):1-9. PubMed ID: 29619050
[TBL] [Abstract][Full Text] [Related]
11. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
12. Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome.
Jiang P; van der Horst C; Kimmig B; Zinsser F; Poppe B; Luetzen U; Juenemann KP; Dunst J; Siebert FA
Brachytherapy; 2017; 16(1):186-192. PubMed ID: 28341011
[TBL] [Abstract][Full Text] [Related]
13. Salvage Reirradiation Options for Locally Recurrent Prostate Cancer: A Systematic Review.
Zhong J; Slevin F; Scarsbrook AF; Serra M; Choudhury A; Hoskin PJ; Brown S; Henry AM
Front Oncol; 2021; 11():681448. PubMed ID: 34568012
[TBL] [Abstract][Full Text] [Related]
14. Population-based patient-reported quality of life outcomes following low-dose-rate versus high-dose-rate brachytherapy monotherapy for low-intermediate risk prostate cancer.
Ong WL; Evans M; Papa N; Williams S; Millar J
J Med Imaging Radiat Oncol; 2023 Oct; 67(7):789-795. PubMed ID: 37828817
[TBL] [Abstract][Full Text] [Related]
15. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
16. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer.
Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423
[TBL] [Abstract][Full Text] [Related]
17. High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes.
Falk AT; Demontoy S; Chamorey E; Chand ME; Gautier M; Azria D; Zaki S; Chevallier D; Cham Kee DL; Hannoun-Lévi JM
Brachytherapy; 2017; 16(5):993-999. PubMed ID: 28754301
[TBL] [Abstract][Full Text] [Related]
18. High-dose-rate brachytherapy boost for locally advanced cervical cancer: Oncological outcome and toxicity analysis of 4 fractionation schemes.
le Guyader M; Lam Cham Kee D; Thamphya B; Schiappa R; Gautier M; Chand-Fouche ME; Hannoun-Levi JM
Clin Transl Radiat Oncol; 2022 Jan; 32():15-23. PubMed ID: 34816022
[TBL] [Abstract][Full Text] [Related]
19. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
20. Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy.
Buchser D; Gomez-Iturriaga A; Melcon JI; Casquero F; Llarena R; Cacicedo J; Bilbao P
J Contemp Brachytherapy; 2016 Dec; 8(6):477-483. PubMed ID: 28115952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]